Skip to content

Shalmali Ghrita and Nishakatakadi Ghanavati after Virechan Karma in Madhumehaja Klaibya (Diabetes Mellitus induced Erectile Dysfunction)

Efficacy of Shalmali Ghrita and Nishakatakadi Ghanavati after Virechan Karma in the management of Madhumehaja Klaibya [Diabetes Mellitus induced Erectile Dysfunction (DMED)] – Standard controlled clinical trial - Nil

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062500
Enrollment
114
Registered
2024-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

None listed

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Male patient in the age group of 25-50 years 2 Patients giving a clinical history of erectile dysfunction and having IIEF - EF score of = 25 3 Patients giving a clinical history of diabetes (DM Type II) and or Fasting blood sugar (FBS) more than 126 mg per dl up to 180 mg per dl and or Postprandial blood sugar (PPBS) more than 140 mg per dl up to 300 mg per dl 4 Glycosylated hemoglobin (HbA1C) more than 6.5%, up to 12%. 5 Early-diagnosed cases are to be included as per the following criteria: • Patient accidentally diagnosed in routine check-up or when appeared with other complaints in the hospital. • Patients already taking conventional medicines or Ayurvedic medicine and who fall within the inclusive criteria mentioned above will be taken into group A (control) and B (trial) respectively (dose adjustment can be done). • Early diagnosed diabetic patients (Maximum 5 years of diabetic history).

Exclusion criteria

Exclusion criteria: 1. Patients having insulin-dependent DM (type 1) and receiving insulin 2. Emergency conditions in cases of DM. 3. Patients with acute or chronic liver disease with elevated liver enzymes. 4. Patients were reported being hypersensitive to any of the proposed trial drugs. 5. Participation in other clinical studies in the past 12 weeks. 6. Takes psychotropic medications that raise blood glucose (e.g., atypical antipsychotics) 7. Patients suffering from Uncontrolled Hypertension (more than 140 by 90mmHg), Hypothyroidism, Nephropathy, CAD (taking allopathy medication for same), and any other chronic comorbid condition. 8. Patients suffering from STD, Carcinoma, AIDS, TB, congenital abnormalities of genital organs, other diseases like Phimosis, Ulceration, Hydrocele, Spinal cord lesions, etc. 9. For any reason, the investigator may consider a subject inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Improvement in IIEF – EF scoreTimepoint: Day 0, 8 Weeks and 12 weeks

Secondary

MeasureTime frame
Improvement in 1. Fasting Blood Sugar (FBS) 2. Post Prandial Blood sugar level (PPBS) 3. Glycosylated haemoglobin (in %) – HbA1CTimepoint: Day 0, 8 Weeks and 12 weeks for 1 and 2 and Day 0, 8 Weeks for 3

Countries

India

Contacts

Public ContactDr Sanjay Kumar Tiwari

All India Institute of Ayurveda, New Delhi

mahtorajaram@yahoo.com8877033663

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026